A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Dermatitis

In brief

The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents.

Key facts

Study ID

NCT03706040

Run by

AbbVie

People needed

172

Starts

2018-12-27

Expected to finish

2021-04-26

Last updated by the study team

2021-11-18

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adults who are ≥ 18 years old and, where locally permissible and approved, adolescent subjects who are at least 12 years old
• a diagnosis of atopic dermatitis (AD) with onset of symptoms at least 2 years prior to Baseline and subject meets Hanifin and Rajka criteria
• moderate to severe AD at the Baseline Visit
• history of inadequate response to previous topical corticosteroid and/or topical calcineurin inhibitor treatments or a medical inability to receive these treatments

You may not qualify if…

• prior exposure to any biologic immunomodulatory agent or Janus kinase (JAK) inhibitor
• concurrent treatment with systemic therapy for AD (biologic or non-biologic) or topical and/or phototherapy treatments

Where it is running

• Cognitive Clinical Trials /ID# 208895 — Scottsdale, Arizona, United States
• Cosmetic Dermatology of Orange County /ID# 205801 — Anaheim, California, United States
• Center for Dermatology Clinical Research /ID# 204950 — Fremont, California, United States
• Integrative Skin Science and Research /ID# 212486 — Sacramento, California, United States
• Cosmetic Laser Dermatology /ID# 210560 — San Diego, California, United States
• Therapeutics Clinical Research /ID# 203422 — San Diego, California, United States
• Colorado Center for Dermatology, PLLC /ID# 216260 — Centennial, Colorado, United States
• Park Avenue Dermatology, PA /ID# 203378 — Orange Park, Florida, United States
• MetroDerm ACC Research /ID# 205958 — Atlanta, Georgia, United States
• Skin Care Physicians of Georgia /ID# 213188 — Macon, Georgia, United States
• University Dermatology and Vein Clinic, LLC /ID# 210702 — Darien, Illinois, United States
• The Indiana Clinical Trials Center /ID# 211618 — Plainfield, Indiana, United States
• Tulane University /ID# 203214 — New Orleans, Louisiana, United States
• DermAssociates /ID# 206189 — Rockville, Maryland, United States
• Oakland Hills Dermatology /ID# 217453 — Auburn Hills, Michigan, United States
• Duplicate_Great Lakes Research, Inc. /ID# 206447 — Bay City, Michigan, United States
• Grekin Skin Institute /ID# 210485 — Warren, Michigan, United States
• Skin Cancer and Dermatology Institute (SCDI) /ID# 213041 — Reno, Nevada, United States
• Psoriasis Treatment Center of Central New Jersey /ID# 203203 — East Windsor, New Jersey, United States
• Darst Dermatology /ID# 215100 — Charlotte, North Carolina, United States
• Dermatologists of Southwest Ohio, Inc /ID# 215104 — Mason, Ohio, United States
• Unity Clinical Research /ID# 217461 — Oklahoma City, Oklahoma, United States
• Oregon Derm & Res. Ctr /ID# 202880 — Portland, Oregon, United States
• Dermatologic SurgiCenter /ID# 208972 — Drexel Hill, Pennsylvania, United States
• UAB Department of Dermatology /ID# 211561 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.